Afinitor Boosts Effectiveness of Hormonal Therapy

Adding Afinitor, an mTOR inhibitor, to tamoxifen helped women with metastatic breast cancer live about four months longer without their disease getting worse, according to a study presented Thursday at SABCS.

MELISSA WEBER
PUBLISHED: 1:00 AM, THU DECEMBER 9, 2010
Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
Adding Afinitor (everolimus) to tamoxifen helped women with metastatic breast cancer live four months longer without their disease getting worse, according to a study presented Thursday at the San Antonio Breast Cancer Symposium.

Researchers randomly assigned 111 women to receive tamoxifen alone or tamoxifen plus Afinitor. Patients getting the combination lived a median of 8.6 months without disease progression, compared with 4.5 months for the tamoxifen-only group. After a median follow-up of around 22 months, nine patients in the combination arm had died compared with 25 deaths in the tamoxifen arm. All patients in this phase 2 trial had estrogen receptor–positive breast cancer that had previously been treated with an aromatase inhibitor, like Femara (letrozole) or Arimidex (anastrozole).

Afinitor—already approved for advanced kidney cancer—works by targeting mTOR, a protein that helps regulate the growth of cancer cells and blood vessels. Side effects associated with Afinitor include mouth ulcers, infections, cough and fatigue.

Three phase 3 studies, nicknamed BOLERO—short for Breast cancer trials of OraL EveROlimus— are now under way testing Afinitor in patients with locally advanced or metastatic breast cancer. one study will look at Afinitor in combination with the HER2-targeted drug Herceptin (trastuzumab) and the chemotherapy drug Taxol (paclitaxel). A second study will test the mTOR inhibitor in combination with Aromasin (exemestane), an aromatase inhibitor used to treat postmenopausal women with estrogen receptor–positive breast cancer. The third study will combine Afinitor with Herceptin and vinorelbine, a chemotherapy agent.

Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
Special Feature
Share Your Art
Related Articles
Flat and Fabulous: Life After Breast Cancer and a Double Mastectomy
Learning to accept my body after a double mastectomy.
Freda: Management of Aggressive Treatment and a Difficult Prognosis
Freda Omaswa talks about how she has coped with the emotional and physical aspects of disease progression and the side effects caused by aggressive cancer treatment, and provides suggestions to patients facing a similar situation. Dr John Marshall remarks on the usefulness of maintaining a journal throughout a cancer journey. After a 19-month battle with metastatic colon carcinoma, Freda passed away quietly in her sleep on February 1, 2016.
Improving Care for Patients with Colorectal Cancer
In this segment, Dr John Marshall discusses the importance of patient-patient connections throughout a cancer journey, and the challenges he faces when advising patients, and their loved ones, of the potential for treatment side effects. Freda Omaswa remarks on areas of cancer care where she feels improvements need to be made, and how her experience as a patient will change her as a physician.After a 19-month battle with metastatic colon carcinoma, Freda passed away quietly in her sleep on February 1, 2016.
Related Videos
Amanda L. Kong on Seeking a Second Opinion for Breast Cancer Care at a High Volume Hospital
Amanda L. Kong, discusses why patients should consider seeking a second opinion for their breast cancer diagnosis and care at a high volume hospital.
Amanda L. Kong on Breast Cancer Care at High Volume Hospitals
This study sought to identify patterns of breast cancer care at high volume hospitals.
Anees B. Chagpar on What to Expect After Contralateral Prophylactic Mastectomy
Anees B. Chagpar, director of the Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses what a patient can expect following a contralateral prophylactic mastectomy.
$auto_registration$